.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A government inquiry recently concluded a major investigation into medical ethics in India. Specifically, it exposed how 30 medical practitioners accepted sponsored foreign trips to Paris and Monaco from AbbVie Pharma. This lavish excursion cost over Rs 1.9 crore. However, a massive controversy erupted when the list forwarded to the National Medical Commission (NMC) contained only 27 names.
In December 2024, the apex committee on pharmaceutical marketing practices ordered the department to send the list of offenders to the NMC. Subsequently, the department delayed sending this list for nine long months. When the NMC finally received the document in September 2025, three names had mysteriously disappeared. Consequently, the medical regulator only received 27 names instead of the original 30. Furthermore, both the Department of Pharmaceuticals and the NMC have refused to publicly reveal the identities of these doctors.
According to the NMC Act, state councils have the primary jurisdiction to investigate professional misconduct. Therefore, the NMC forwarded the 27 names to nine different state medical councils for inquiry and appropriate action. Meanwhile, a Right to Information (RTI) query filed with the Prime Minister's Office revealed that the Kerala State Medical Council (KSMC) received one of these names. Currently, the KSMC is seeking an explanation from the concerned doctor. However, the exact names of the other eight states involved remain undisclosed. Additionally, the NMC can take over the probe if the state councils fail to decide within six months. Specifically, NMC Chairperson Dr. Abhijat Sheth assured that the commission will act firmly as appropriate.
Q1: Why are the doctors being investigated?
Specifically, a government inquiry found them guilty of accepting a luxury trip from AbbVie Pharma. This act clearly violates medical ethics.
Q2: Why did only 27 names reach the NMC?
Although 30 doctors were initially found guilty, the list forwarded to the commission contained only 27 names. Currently, the department has not explained why three names disappeared.
Q3: What action can state medical councils take?
State medical councils have the power to investigate ethical misconduct. Consequently, they can suspend or cancel medical licenses if necessary.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A government inquiry found 30 doctors guilty of accepting a ₹1.9 crore trip, but only 27 names reached the National Medical Commission for action....
4 months ago
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
Recent clinical studies reveal maternal autoantibodies targeting IL-1RA as potential triggers for preterm labor, opening avenues for targeted cytokine therapies. Concurrently, new perioperative findings show inhaled cannabis increases propofol requirements during upper endoscopy compared to oral edible consumption.
Today
In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
